Valspodar
drugOn this page
Also known as AmdrayPSC 833PSC833SDZ PSC 833SDZ-PSC 833PSC-833 (Valspodar)PSC-833(Valspodar)
Summary
Valspodar (CHEMBL1086218) is a phase-3 clinical-stage protein targeting ABCB1; indicated across 21 conditions including myelodysplastic syndrome and acute monocytic leukemia.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Protein
- Targets: 1 (ABCB1)
- Indications: 21 conditions
- Clinical trials: 12
- Chemistry: 1214.6 Da · C63H111N11O12
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1086218 |
| Name | Valspodar |
| Type | Protein |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 5281884 |
| Molecular formula | C63H111N11O12 |
| Molecular weight | 1214.6 |
| InChIKey | YJDYDFNKCBANTM-QCWCSKBGSA-N |
SMILES: C/C=C/C[C@@H](C)C(=O)[C@H]1C(=O)N[C@H](C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)C(C)C
IUPAC name: (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-1,4,7,10,12,15,19,25,28-nonamethyl-33-[(E,2R)-2-methylhex-4-enoyl]-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
Also known as: Amdray, PSC 833, PSC833, SDZ PSC 833, SDZ-PSC 833, Valspodar, PSC-833 (Valspodar), PSC-833(Valspodar), VALSPODAR
Patent coverage: 1,502 distinct patent families (5,970 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,952 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| ABCB1 | ABCB1 | Inhibition | 5.89 | 0.4% | P08183 |
Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Multidrug resistance-associated protein 1, ATP-dependent translocase ABCB1, ATP-binding cassette sub-family C member 2.
Bioactivity
ChEMBL activities: 9 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| ABCB1 | 7.65 | IC50 | 22.2 | nM | CHEMBL_ACT_11000833 |
| ABCB1 | 6.96 | EC50 | 110 | nM | CHEMBL_ACT_11000818 |
| ABCB1 | 6.96 | IC50 | 110 | nM | CHEMBL_ACT_11000842 |
| ABCB1 | 6.87 | Ki | 134 | nM | CHEMBL_ACT_11002259 |
| ABCB1 | 6.54 | IC50 | 291 | nM | CHEMBL_ACT_11000854 |
| ABCB1 | 6.39 | EC50 | 410 | nM | CHEMBL_ACT_11000820 |
| ABCB1 | 6.3 | IC50 | 501.2 | nM | CHEMBL_ACT_10954678 |
| ABCB1 | 5.97 | IC50 | 1060 | nM | CHEMBL_ACT_11000896 |
| ABCB1 | 5.89 | Ki | 1300 | nM | CHEMBL_ACT_11002320 |
Target pathways
Aggregated over 1 target gene(s): ABCB1.
Top Reactome pathways
7 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Abacavir transmembrane transport | 1 | ABCB1 |
| Abacavir ADME | 1 | ABCB1 |
| Transport of small molecules | 1 | ABCB1 |
| ABC-family protein mediated transport | 1 | ABCB1 |
| Drug ADME | 1 | ABCB1 |
| Atorvastatin ADME | 1 | ABCB1 |
| Prednisone ADME | 1 | ABCB1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| G2/M transition of mitotic cell cycle | 1 |
| response to hypoxia | 1 |
| placenta development | 1 |
| xenobiotic metabolic process | 1 |
| female pregnancy | 1 |
| lactation | 1 |
| circadian rhythm | 1 |
| response to xenobiotic stimulus | 1 |
| hormone transport | 1 |
| response to progesterone | 1 |
| response to vitamin A | 1 |
| response to vitamin D | 1 |
| response to glucagon | 1 |
| maintenance of blood-brain barrier | 1 |
| cellular response to mycotoxin | 1 |
Indications & clinical
Indications
21 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| myelodysplastic syndrome | 3 | MONDO:0018881 | EFO:0000198 |
| acute monocytic leukemia | 3 | MONDO:0007896 | EFO:0000221 |
| acute myelomonocytic leukemia M4 | 3 | MONDO:0018871 | EFO:0000223 |
| leukemia | 3 | MONDO:0005059 | EFO:0000565 |
| plasma cell myeloma | 3 | MONDO:0009693 | EFO:0001378 |
| acute megakaryoblastic leukemia | 3 | MONDO:0018872 | EFO:0003025 |
| acute myeloblastic leukemia without maturation | 3 | MONDO:0005224 | EFO:0003027 |
| acute basophilic leukemia | 3 | MONDO:0019458 | EFO:0003029 |
| acute erythroid leukemia | 3 | MONDO:0017858 | EFO:0000218 |
| acute myeloblastic leukemia with maturation | 3 | MONDO:0020320 | EFO:0003028 |
| plasma cell neoplasm | 3 | MONDO:0004959 | EFO:0000200 |
| acute myeloid leukemia | 3 | MONDO:0018874 | EFO:0000222 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| lymphoma | 1 | MONDO:0005062 | EFO:0000574 |
| renal cell carcinoma | 1 | MONDO:0005086 | EFO:0000681 |
| sarcoma | 1 | MONDO:0005089 | EFO:0000691 |
| kidney neoplasm | 1 | MONDO:0021163 | EFO:0003865 |
| ovarian cancer | 1 | MONDO:0008170 | MONDO:0008170 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 12.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 5 |
| PHASE3 | 4 |
| PHASE2 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00002878 | PHASE3 | COMPLETED | Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| NCT00003190 | PHASE3 | COMPLETED | Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia |
| NCT00005823 | PHASE3 | COMPLETED | Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome |
| NCT00006363 | PHASE3 | COMPLETED | Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia |
| NCT00002826 | PHASE2 | COMPLETED | Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer |
| NCT00002937 | PHASE2 | COMPLETED | Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer |
| NCT00004217 | PHASE2 | COMPLETED | S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
| NCT00001302 | PHASE1 | COMPLETED | A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833 |
| NCT00001383 | PHASE1 | COMPLETED | A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 |
| NCT00001570 | PHASE1 | COMPLETED | A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer |
| NCT00002912 | PHASE1 | COMPLETED | Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia |
| NCT00003207 | PHASE1 | COMPLETED | Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi’s Sarcoma or Other Advanced Cancers |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
123 molecules share ≥1 primary target. Top 60 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| TRAMETINIB | ChEMBL + PubChem | Phase 4 (approved) | ABCB1 |
| AMIODARONE | ChEMBL | Phase 4 (approved) | ABCB1 |
| AMLODIPINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| ARIPIPRAZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| ASTEMIZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| ATAZANAVIR | ChEMBL | Phase 4 (approved) | ABCB1 |
| AZELASTINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| BROMOCRIPTINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| CARVEDILOL | ChEMBL | Phase 4 (approved) | ABCB1 |
| CERITINIB | ChEMBL | Phase 4 (approved) | ABCB1 |
| CHLORPROMAZINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| CLARITHROMYCIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| CLOFAZIMINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| CLOTRIMAZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| CYCLOSPORINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| DARUNAVIR | ChEMBL | Phase 4 (approved) | ABCB1 |
| DAUNORUBICIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| DESLORATADINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| DILTIAZEM | ChEMBL | Phase 4 (approved) | ABCB1 |
| DIPYRIDAMOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| DONEPEZIL | ChEMBL | Phase 4 (approved) | ABCB1 |
| DOXORUBICIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| EBASTINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| EMETINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| ERGOTAMINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| ERLOTINIB | ChEMBL | Phase 4 (approved) | ABCB1 |
| ERYTHROMYCIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| ETRAVIRINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| FELODIPINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| FENTANYL | ChEMBL | Phase 4 (approved) | ABCB1 |
| FLUPHENAZINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| GEFITINIB | ChEMBL | Phase 4 (approved) | ABCB1 |
| HALOPERIDOL | ChEMBL | Phase 4 (approved) | ABCB1 |
| IMATINIB | ChEMBL | Phase 4 (approved) | ABCB1 |
| INDOMETHACIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| ITRACONAZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| IVERMECTIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| KETOCONAZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| LANSOPRAZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| LEFAMULIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| LONAFARNIB | ChEMBL | Phase 4 (approved) | ABCB1 |
| LOPERAMIDE | ChEMBL | Phase 4 (approved) | ABCB1 |
| LOPINAVIR | ChEMBL | Phase 4 (approved) | ABCB1 |
| LORATADINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| LOVASTATIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| METHADONE | ChEMBL | Phase 4 (approved) | ABCB1 |
| MIBEFRADIL | ChEMBL | Phase 4 (approved) | ABCB1 |
| MICONAZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| MIDOSTAURIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| MITOXANTRONE | ChEMBL | Phase 4 (approved) | ABCB1 |
| NEFAZODONE | ChEMBL | Phase 4 (approved) | ABCB1 |
| NELFINAVIR | ChEMBL | Phase 4 (approved) | ABCB1 |
| NICARDIPINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| NINTEDANIB | ChEMBL | Phase 4 (approved) | ABCB1 |
| NISOLDIPINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| OMEPRAZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| PACLITAXEL | ChEMBL | Phase 4 (approved) | ABCB1 |
| PANTOPRAZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| PAROXETINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| PIMOZIDE | ChEMBL | Phase 4 (approved) | ABCB1 |
Related Atlas pages
- Genes: ABCB1
- Diseases: myelodysplastic syndrome, acute monocytic leukemia, leukemia, plasma cell myeloma, acute megakaryoblastic leukemia, acute myeloblastic leukemia without maturation, acute basophilic leukemia, acute myeloblastic leukemia with maturation, plasma cell neoplasm, acute myeloid leukemia
- Drugs: Trametinib, Amiodarone, Amlodipine, Aripiprazole, Astemizole, Atazanavir, Azelastine, Bromocriptine, Carvedilol, Ceritinib, Chlorpromazine, Clarithromycin, Clofazimine, Clotrimazole, Cyclosporine, Darunavir, Daunorubicin, Desloratadine, Diltiazem, Dipyridamole, Donepezil, Doxorubicin, Ebastine, Emetine, Ergotamine, Erlotinib, Erythromycin, Etravirine, Felodipine, Fentanyl, Fluphenazine, Gefitinib, Haloperidol, Imatinib, Indomethacin, Itraconazole, Ivermectin, Ketoconazole, Lansoprazole, Lefamulin, Lonafarnib, Loperamide, Lopinavir, Loratadine, Lovastatin, Methadone, Mibefradil, Miconazole, Midostaurin, Mitoxantrone, Nefazodone, Nelfinavir, Nicardipine, Nintedanib, Nisoldipine, Omeprazole, Paclitaxel, Pantoprazole, Paroxetine, Pimozide